RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan.
The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Researchers at a Japanese cancer center have found that the more alcohol premenopausal Japanese women drink, the more likely they are to develop breast cancer.
A research group at Aichi Cancer Center in the city of Nagoya collected data from more than 158,000 Japanese women over a period of around 14 years. It analyzed the data to study the link between alcohol and breast cancer.
About 2,200 of the women developed breast cancer. The researchers found that premenopausal women who drink alcohol almost every day have 1.37 times higher risk than those who do not drink alcohol.
They also found that premenopausal women who drink more than 23 grams of alcohol a day have 1.74 times higher risk than those who do not drink alcohol.